tomation of the radiosynthesis and purification procedures for [18F]Fluspidine preparation, a new radiotracer for clinical investigations in PET imaging of σ1 receptors in brain. Applied Radiation and Isotopes, Elsevier, 2014, 84, pp.
Introduction
σ 1 receptors, initially postulated as opioid receptors, are remarkably distinct from all previously characterized mammalian proteins (Kekuda et al., 1996; Martin et al., 1976) . These interesting ligand-operated molecular chaperones are widely distributed in peripheral organs such as liver, lung or heart and they are particularly expressed in the central nervous system (Alonso et al., 2000; Kekuda et al., 1996; Kitaichi et al., 2000) . As the σ 1 receptors are involved in several neurological diseases such as depression, dementia, schizophrenia, Alzheimer's or Parkinson's diseases (Hayashi et al., 2011; Su et al., 2010; van Waarde et al., 2010) , they represent an attractive target for the development of novel diagnostic imaging agents in the brain (Brust et al., 2013) . To date, no optimal PET radiotracer for clinical imaging of the σ 1 receptors is available. Although [ 11 C]SA4503 has recently been studied as a σ 1 receptor tracer for use in humans Kimura et al., 2007; Sakata et al., 2007; Toyohara et al., 2009 ) there is still a need to develop more specific 18 F-labelled derivatives which would allow broader clinical application by use of the satellite concept. Therefore, we recently developed a series of fluorinated radiotracers with a spiro[benzofuranpiperidine] scaffold (Große Große Maestrup et al., 2011; Maisonial et al., 2011) . Among them, [ 18 F]Fluspidine demonstrated a high potential for neuroimaging of σ 1 receptors with PET (Scheme 1). Preliminary preclinical studies Maisonial et al., 2012) revealed a high specific brain uptake and metabolic stability in mice. Further detailed preclinical and first clinical studies with this radiotracer are scheduled by our group and require the transfer and adaptation of the production of [ 18 F]Fluspidine to an automated radiosynthesis module ( Figure 1 ). Indeed, automation is an essential feature for routine preparation of 18 F-labelled radiopharmaceuticals for human applications, as it ensures reliable radiolabelling yields, optimal radiochemical purities, and the decrease of radiation exposure to medical personnel. As prerequisite for the application of [ 18 F]Fluspidine in humans, we herein report on the development of a cGMP (Current Good Manufacturing Practice)-oriented automated radiosynthesis of this radiotracer.
The optimisation of the one-step nucleophilic substitution reaction from the corresponding tosylate precursor 1 as well as investigations of the semi-preparative RP-HPLC purification and subsequent formulation are described.
Materials and methods

General
Solvents and reagents were purchased of highest commercially available quality and applied without further purification from Merck KGaA (Darmstadt, Germany), Sigma-Aldrich Co.
LLC. (Taufkirchen, Germany), Carl Roth GmbH + Co. KG (Karlsruhe, Germany), VWR International GmbH (Darmstadt, Germany) and Fisher Scientific GmbH (Schwerte, Germany Processed TLC plates were exposed to 18 F-sensitive storage phosphor screens (BAS-TR2025, FUJIFILM Co., Tokyo, Japan), and image plates were analyzed using a bioimaging analyzer system (BAS-1800 II, BASReader 2.26 Beta and AIDA 2.31 Image Analyzer software;
Raytest GmbH, Straubenhardt, Germany, and FUJIFILM Co., Tokyo, Japan). Analytical GmbH, Straubenhardt, Germany). 
Radiosynthesis of [
Results and discussion
3.1. Radiosynthetic procedure [ 18 F]2 was prepared starting from its corresponding tosylate precursor 1 (Scheme 1) using a TRACERlab TM FX F-N synthesis module. The synthesizer setup is depicted in Figure 1 .
Briefly the incorporation of [ 18 F]fluoride in the precursor 1 was performed in acetonitrile at 85 °C for 15 minutes. Compared to the manual procedure we previously reported , higher labelling efficiencies of 83 ± 9% (n = 5) vs. 60-70% were achieved. The reaction time could be reduced from 25 to 15 min. Moreover, these results were obtained using slightly smaller amounts of precursor (1.7-2.5 mg vs. 2.5-3 mg). As a result, the purification process of the crude reaction mixture was simplified, since an intermediate step of a pre-purification on a SPE cartridge to remove most of the non-reacted precursor was not necessary. The crude reaction mixture could be applied directly on the semi-preparative HPLC column, equipped with a small pre-column. Radioactivity balance showed that only 4.3 ± 0.8% (n = 6) of the radioactivity was lost in the reactor after transfer to the semi-preparative HPLC system. To remove the HPLC eluent and render possible the final formulation of [ 18 F]2, the collected HPLC fraction was diluted with water. The desired radiotracer was then trapped on an equilibrated Sep-Pak ® Plus C 18 cartridge, washed with water and finally eluted using absolute ethanol, instead of formerly used methanol . Using these optimized conditions, only 1.6 ± 0.7% (n = 7) of the total radioactivity was lost on the cartridge during the SPE procedure.
With this entire radiosynthesis process [ 18 F]Fluspidine was produced within 59 ± 4 min (n = 8) with a radiochemical purity of 99.4 ± 0.5% (n = 11, analytical HPLC chromatogram see figure 2 ), a decay corrected radiochemical yield of 37 ± 8% (n = 9) and a specific activity of 176.6 ± 52.0 GBq/µmol (n = 5, determination via analytical RP-HPLC using UV/mass calibration). [ 18 F]2 also showed good radioactive stability in the final solution for injections in vivo (> 97.1%) even 2 h at 40 °C after production. Altogether, a basis could be established for the design of a procedure for GMP compliant production of [ 18 F]Fluspidine.
Semi-preparative HPLC purification
As reported previously , the purification of [ 18 F]2 succeeded with a Multospher ® RP18-AQ column using a neutral buffered, aqueous acetonitrile eluent. Thereby (i) the two appearing radioactive species were identified as radioactive fluoride (Figure 3 The Multospher ® RP18-AQ column is a RP phase with polar as well as hydrophobic properties, because hydroxyethyl and C18 groups are bound to the silica. Since this mixed characteristic seems to be appropriate for the separation of our crude reaction mixture, we selected two further columns with similar properties. The ReproSil-Pur ® C18-AQ and the Nucleodur C18 Pyramid ® also provide hydroxyethyl and C18 spacers, but differ regarding the silica support. With the ReproSil-Gold ® column, we tested a strong hydrophobic phase which is base-deactivated by double bound end-capping resulting in 20% carbon content compared to 14-15% for the AQ phases. In particular regarding the peak shape this phase was promising since 2, as a basic compound due to its tertiary amine, can strongly interact with free silanol groups under neutral or basic conditions (Neue et al., 2001; Wenzel et al., 2010) . Furthermore, we investigated two different buffer systems: aqueous ammonium acetate (pH 6.8) and aqueous sodium dihydrogen phosphate (pH ~ 5). With the aim to lower the risk of remaining acetonitrile in product formulations (allowed percentage according to United States Pharmacopoeia: 0.04% (Hung, 2002) ) we tested ethanol as organic modifier, which would be more appropriate regarding a future clinical application.
With the ReproSil-Pur ® C18-AQ phase similar properties and elution profiles as for the Multospher ® RP18-AQ phase were observed. However, using 56% MeCN/20 mM NH 4 OAc aq.
the retention time of [ 18 F]2 was somewhat reduced and accompanied by a clear and advantageous separation from the UV active by-products (Figure 4 ).
Additionally, peak tailing observed with Multospher ® RP18-AQ could be decreased significantly and resulted in a reduction of the collected volume (3 mL compared to formerly 6-7 mL). According to our previous experiences using the ReproSil-Pur ® C18-AQ column, all investigated combinations of mobile phases exhibited separations with good peak shape properties. However, regarding the separation of [ 18 F]2 from its UV active by-products, the MeCN/20 mM NH 4 OAc aq. eluent system was more suitable than EtOH/20 mM NH 4 OAc aq.
and MeCN/25 mM NaH 2 PO 4aq. . With ethanol as organic modifier, the back pressure of this column was observed to be in a tolerable range of 70-75 bar. Comparing the two different buffer systems, we observed a decreased retention of [ 18 F]2 when the slightly acidic NaH 2 PO 4 was used. Therefore the content of MeCN in the eluent mixture was reduced to achieve a separation from the UV by-products. This trend was observed for all columns we tested and might be caused by the slightly lower pH value or by the different counter ions used (Na + vs.
NH 4 + ).
Using the Nucleodur C18 Pyramid ® column and acetonitrile as organic modifier, [ 18 F]2 could be also separated within 20 min and a good peak shape was observed. However, a single UV by-product was eluted shortly in front of the radiotracer, which limits the quality of this separation system ( Figure 5) . In contrast to the ReproSil-Pur ® C18-AQ column, a high back pressure was observed with ethanolic eluents and the flow rate had to be reduced (1-2 mL/min). This resulted in a strong increase of retention times, unsuitable for the separation of a 18 F-labelled radiotracer.
Further, the strong hydrophobic ReproSil-Gold ® C18 phase was investigated, offering lowest silanol activity and high pH-stability. Using acetonitrile as organic modifier, [ 18 F]2 could be separated from the UV by-products within 20 min. Interestingly, independent of the buffer system used for the purification a considerable peak tailing was observed when using MeCN as organic modifier, which could be suppressed with ethanol. However, as depicted in Figure  6 the separation with ethanol was not appropriate due to the almost co-elution of a single UV by-product.
Summing up, a feasible separation of [ 18 F]2 could be achieved on combinations out of a serial of four different commercially available stationary RP and three mobile phases. Thereof, to our opinion the most suitable system consisted of the ReproSil-Pur ® C18-AQ phase and ammonium acetate buffered acetonitrile.
Conclusion
The radiosynthesis and the purification of [ 18 F]2 was successfully transferred onto an automated synthesis module and is routinely used in our laboratory for pre-clinical studies using this radiotracer. This rapid and versatile radiosynthetic approach will enhance the accessibility of [ 18 F]Fluspidine, a potent novel ligand for PET imaging of σ 1 receptors in the brain, for widespread production in future clinical studies. The development of the corresponding fully cGMP compliant process is currently under investigation. 
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